XPRESS Portfolio Over 150 targets enabled for off-the-shelf crystallography Broad range of targets and classes Established protocols for protein production and crystallization Average turn-around time of 2 months

Leverage our platform of biophysical methods to accelerate your research on targeted protein degradation. At DDC 2023, WuXi AppTec scientists presented an in-depth panel of assays to support the characterization of bifunctional small molecules. Our cutting-edge services include target protein ubiquitination and degradation assays, techniques to evaluate binary binding, and proximity assays to measure ternary …Read More >

Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as …Read More >

We offer a comprehensive platform of biophysical screening assays to measure protein binding, thermodynamics, stoichiometry, protein quality, and kinetics to accelerate your drug discovery programs.

Discover our comprehensive structure generation platform for challenging targets, with our high resolution and high throughput crystallization services to support hit finding through to lead optimization.

With a focus on quality and stability, gain access to our established systems, strategies, and advanced co-expression vectors to address even the most significant challenges of recombinant protein production.

In this month’s newsletter, learn more about our comprehensive panel of CDK4/6 inhibitor-resistant breast cancer models and in vitro imaging assays for compound profiling.  We also showcase our recent publications describing the development of HBV antigen inhibitors and noncovalent inhibitors of the SARS-CoV-2 3C-like protease (3CLpro).